There are 594 resources available
417P - Deep neural networks prognosis for lung cancer with non-omics data: African cohort
Presenter: Hassan Abdelilah Tafenzi
Session: Poster Display session
418P - Low fT3/fT4 ratio as a proxy for muscle wasting in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab: A metabolic multi-omic analysis
Presenter: Lorenzo Belluomini
Session: Poster Display session
419P - Predictors and outcomes of non-small cell lung carcinoma (NSCLC) patients following severe immune checkpoint inhibitor (ICI) toxicity: A real-world UK multi-centre study
Presenter: Umair Mahmood
Session: Poster Display session
420P - Predictive value of inflammatory scores for the development of clinical complications in lung cancer: A prospective study by the European Lung Cancer Working Party (ELCWP)
Presenter: Ilann Oueslati
Session: Poster Display session
421P - Antibiotic prescription patterns and their association with outcomes in patients with advanced non-small cell lung cancer (aNSCLC) treated with immune checkpoint inhibitors (ICI)
Presenter: Lea Knez
Session: Poster Display session
422P - Acute pneumonitis in patients receiving thoracic radiotherapy and pre-treated with immune checkpoint inhibitors
Presenter: Giulia Mazzaschi
Session: Poster Display session
423P - Toxicity and survival following lung radiotherapy in patients with interstitial lung abnormalities and interstitial lung disease
Presenter: Sarah Bowen Jones
Session: Poster Display session
Resources:
Abstract
424P - Real-world data of lenvatinib in patients with thymic epithelial tumors (TETs)
Presenter: Álvaro López Gutiérrez
Session: Poster Display session
425P - Real-world data of everolimus in patients with thymic epithelial tumors (TETs)
Presenter: Álvaro López Gutiérrez
Session: Poster Display session
426P - Ototoxicity and safety profile of capmatinib in NSCLC: Insights from real-world FAERS data (2020–2023)
Presenter: Siqi Xu
Session: Poster Display session
Resources:
Abstract